Impact of Fluid Status on Liver Elastography and T1-mapping Results in Patients Undergoing CMR.
- Conditions
- CMRNAFLD/MAFLDLiver Fibrosis
- Registration Number
- NCT05239260
- Lead Sponsor
- Medical University of Vienna
- Brief Summary
Correlation between CMR T1-times, liver T1-times, fibroscan and fluid status to identify the correlation and pathogenesis of liver disease in patients with heart disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
- Referred for Cardiovascular Magnetic Resonance Imaging
Exclusion Criteria
- Non-compatible Devices
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Impact of fluid status on liver elastography and T1-times 5 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link fluid status to liver fibrosis progression in NAFLD/MAFLD patients with heart disease?
How does liver T1-mapping correlate with fibrosis stages in NAFLD/MAFLD patients undergoing CMR compared to standard-of-care methods like FibroScan?
Which biomarkers are most predictive of liver disease severity in patients with both NAFLD/MAFLD and heart failure?
What are the potential adverse events associated with CMR-based liver elastography in patients with fluid overload conditions?
How do T1-mapping techniques compare to other non-invasive methods in assessing hepatic steatosis and fibrosis in MAFLD patients?
Trial Locations
- Locations (1)
Medical University Vienna
🇦🇹Vienna, Austria
Medical University Vienna🇦🇹Vienna, AustriaAndreas KammerlanderContact0043 1 4040048595andreas.kammerlander@meduniwien.ac.at